Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

The Effects of a 10-wk Outpatient Pulmonary Rehabilitation Program on Exercise Performance, Muscle Strength, Soluble Biomarkers, and Quality of Life in Patients With Pulmonary Hypertension.

Koudstaal T, Wapenaar M, van Ranst D, Beesems R, van den Toorn L, van den Bosch A, Chandoesing P, Boomars K.

J Cardiopulm Rehabil Prev. 2019 Nov;39(6):397-402. doi: 10.1097/HCR.0000000000000443.

PMID:
31592929
2.

The impact of the new Global Lung Function Initiative T LCO reference values on trial inclusion for patients with idiopathic pulmonary fibrosis.

Wapenaar M, Miedema JR, Lammering CJ, Mertens FW, Wijsenbeek MS.

Eur Respir J. 2019 Jan 31;53(2). pii: 1801895. doi: 10.1183/13993003.01895-2018. Print 2019 Feb. No abstract available.

PMID:
30760543
3.

Correction to: Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.

Wapenaar M, Twiss J, Wagenaar M, Seijkens P, van den Toorn L, Stepanous J, Heaney A, van den Bosch A, Boomars KA.

Neth Heart J. 2018 Nov;26(11):579. doi: 10.1007/s12471-018-1158-5.

4.

A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers.

Moor CC, Wapenaar M, Miedema JR, Geelhoed JJM, Chandoesing PP, Wijsenbeek MS.

Respir Res. 2018 May 29;19(1):105. doi: 10.1186/s12931-018-0810-3.

5.

Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis.

Broos CE, Wapenaar M, Looman CWN, In 't Veen JCCM, van den Toorn LM, Overbeek MJ, Grootenboers MJJH, Heller R, Mostard RL, Poell LHC, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Eur Respir J. 2018 Jan 18;51(1). pii: 1702089. doi: 10.1183/13993003.02089-2017. Print 2018 Jan. No abstract available.

6.

No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis.

Broos CE, Poell LHC, Looman CWN, In 't Veen JCCM, Grootenboers MJJH, Heller R, van den Toorn LM, Wapenaar M, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B.

Respir Med. 2018 May;138S:S31-S37. doi: 10.1016/j.rmed.2017.10.022. Epub 2017 Oct 31.

PMID:
29137908
7.

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM, Wapenaar M, Cottin V, Wijsenbeek MS.

Eur Respir J. 2017 Oct 19;50(4). pii: 1701157. doi: 10.1183/13993003.01157-2017. Print 2017 Oct. No abstract available.

8.

Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.

Wapenaar M, Patel AS, Birring SS, Domburg RTV, Bakker EW, Vindigni V, Sköld CM, Cottin V, Vancheri C, Wijsenbeek MS.

Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.

9.

[German Validation of the "King's Brief Interstitial Lung Disease (K-Bild) Health Status Questionnaire"].

Kreuter M, Birring SS, Wijsenbeek M, Wapenaar M, Oltmanns U, Costabel U, Bonella F.

Pneumologie. 2016 Nov;70(11):742-746. Epub 2016 Sep 21. German.

10.

Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.

Wapenaar M, Twiss J, Wagenaar M, Seijkens P, van den Toorn L, Stepanous J, Heaney A, van den Bosch A, Boomars KA.

Neth Heart J. 2016 Jun;24(6):417-424. doi: 10.1007/s12471-016-0849-z. Erratum in: Neth Heart J. 2018 Nov;26(11):579.

11.

Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.

Van Manen MJ, Wapenaar M, Strookappe B, Drent M, Elfferich M, de Vries J, Gosker HR, Birring SS, Patel AS, van den Toorn L, van den Blink B, Boomars K, Hoitsma E, Wijsenbeek MS.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):75-82.

PMID:
27055839
12.

A multi-platform flow device for microbial (co-) cultivation and microscopic analysis.

Hesselman MC, Odoni DI, Ryback BM, de Groot S, van Heck RG, Keijsers J, Kolkman P, Nieuwenhuijse D, van Nuland YM, Sebus E, Spee R, de Vries H, Wapenaar MT, Ingham CJ, Schroën K, Martins dos Santos VA, Spaans SK, Hugenholtz F, van Passel MW.

PLoS One. 2012;7(5):e36982. doi: 10.1371/journal.pone.0036982. Epub 2012 May 14.

13.

Functional characterization of mutations in the myosin Vb gene associated with microvillus inclusion disease.

Szperl AM, Golachowska MR, Bruinenberg M, Prekeris R, Thunnissen AM, Karrenbeld A, Dijkstra G, Hoekstra D, Mercer D, Ksiazyk J, Wijmenga C, Wapenaar MC, Rings EH, van IJzendoorn SC.

J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):307-13. doi: 10.1097/MPG.0b013e3181eea177.

14.

Intestinal barrier gene variants may not explain the increased levels of antigliadin antibodies, suggesting other mechanisms than altered permeability.

Wolters VM, Alizadeh BZ, Weijerman ME, Zhernakova A, van Hoogstraten IM, Mearin ML, Wapenaar MC, Wijmenga C, Schreurs MW.

Hum Immunol. 2010 Apr;71(4):392-6. doi: 10.1016/j.humimm.2010.01.016. Epub 2010 Feb 4.

PMID:
20096742
15.

Inflammatory bowel disease and celiac disease: overlaps in the pathology and genetics, and their potential drug targets.

Festen EA, Szperl AM, Weersma RK, Wijmenga C, Wapenaar MC.

Endocr Metab Immune Disord Drug Targets. 2009 Jun;9(2):199-218. Review.

PMID:
19519468
16.

Molecular diagnosis of celiac disease: are we there yet?

Romanos J, Rybak A, Wijmenga C, Wapenaar MC.

Expert Opin Med Diagn. 2008 Apr;2(4):399-416. doi: 10.1517/17530059.2.4.399.

PMID:
23495707
17.

Newly identified genetic risk variants for celiac disease related to the immune response.

Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, Gwilliam R, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJ, Mearin ML, Verbeek WH, Trimble V, Stevens FM, O'Morain C, Kennedy NP, Kelleher D, Pennington DJ, Strachan DP, McArdle WL, Mein CA, Wapenaar MC, Deloukas P, McGinnis R, McManus R, Wijmenga C, van Heel DA.

Nat Genet. 2008 Apr;40(4):395-402. doi: 10.1038/ng.102. Epub 2008 Mar 2.

18.

Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis.

Wapenaar MC, Monsuur AJ, van Bodegraven AA, Weersma RK, Bevova MR, Linskens RK, Howdle P, Holmes G, Mulder CJ, Dijkstra G, van Heel DA, Wijmenga C.

Gut. 2008 Apr;57(4):463-7. Epub 2007 Nov 7.

PMID:
17989107
19.

A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21.

van Heel DA, Franke L, Hunt KA, Gwilliam R, Zhernakova A, Inouye M, Wapenaar MC, Barnardo MC, Bethel G, Holmes GK, Feighery C, Jewell D, Kelleher D, Kumar P, Travis S, Walters JR, Sanders DS, Howdle P, Swift J, Playford RJ, McLaren WM, Mearin ML, Mulder CJ, McManus R, McGinnis R, Cardon LR, Deloukas P, Wijmenga C.

Nat Genet. 2007 Jul;39(7):827-9. Epub 2007 Jun 10.

20.

Neutrophil recruitment and barrier impairment in celiac disease: a genomic study.

Diosdado B, van Bakel H, Strengman E, Franke L, van Oort E, Mulder CJ, Wijmenga C, Wapenaar MC.

Clin Gastroenterol Hepatol. 2007 May;5(5):574-81. Epub 2007 Mar 2.

PMID:
17336591
21.

The SPINK gene family and celiac disease susceptibility.

Wapenaar MC, Monsuur AJ, Poell J, van 't Slot R, Meijer JW, Meijer GA, Mulder CJ, Mearin ML, Wijmenga C.

Immunogenetics. 2007 May;59(5):349-57. Epub 2007 Feb 27.

22.

A functional candidate screen for coeliac disease genes.

Curley CR, Monsuur AJ, Wapenaar MC, Rioux JD, Wijmenga C.

Eur J Hum Genet. 2006 Nov;14(11):1215-22. Epub 2006 Jul 12.

23.

Association analysis of MYO9B gene polymorphisms with celiac disease in a Swedish/Norwegian cohort.

Amundsen SS, Monsuur AJ, Wapenaar MC, Lie BA, Ek J, Gudjónsdóttir AH, Ascher H, Wijmenga C, Sollid LM.

Hum Immunol. 2006 Apr-May;67(4-5):341-5. Epub 2006 May 3.

PMID:
16720215
24.

Genetic and functional analysis of pyroglutamyl-peptidase I in coeliac disease.

Monsuur AJ, Stepniak D, Diosdado B, Wapenaar MC, Mearin ML, Koning F, Wijmenga C.

Eur J Gastroenterol Hepatol. 2006 Jun;18(6):637-44.

PMID:
16702853
25.

A novel splicing mutation in KCNQ2 in a multigenerational family with BFNC followed for 25 years.

de Haan GJ, Pinto D, Carton D, Bader A, Witte J, Peters E, van Erp G, Vandereyken W, Boezeman E, Wapenaar MC, Boon P, Halley D, Koeleman BP, Lindhout D.

Epilepsia. 2006 May;47(5):851-9.

26.

Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect.

Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, Franke L, van't Slot R, van Belzen MJ, Lavrijsen IC, Diosdado B, Daly MJ, Mulder CJ, Mearin ML, Meijer JW, Meijer GA, van Oort E, Wapenaar MC, Koeleman BP, Wijmenga C.

Nat Genet. 2005 Dec;37(12):1341-4. Epub 2005 Nov 13.

PMID:
16282976
27.

A combined genetics and genomics approach to unravelling molecular pathways in coeliac disease.

Wapenaar MC, Wijmenga C.

Novartis Found Symp. 2005;267:113-34; discussion 134-44.

PMID:
15999804
28.

No genetic association of the human prolyl endopeptidase gene in the Dutch celiac disease population.

Diosdado B, Stepniak DT, Monsuur AJ, Franke L, Wapenaar MC, Mearin ML, Koning F, Wijmenga C.

Am J Physiol Gastrointest Liver Physiol. 2005 Sep;289(3):G495-500. Epub 2005 May 12.

29.

The interferon gamma gene in celiac disease: augmented expression correlates with tissue damage but no evidence for genetic susceptibility.

Wapenaar MC, van Belzen MJ, Fransen JH, Sarasqueta AF, Houwen RH, Meijer JW, Mulder CJ, Wijmenga C.

J Autoimmun. 2004 Sep;23(2):183-90.

PMID:
15324937
30.

A microarray screen for novel candidate genes in coeliac disease pathogenesis.

Diosdado B, Wapenaar MC, Franke L, Duran KJ, Goerres MJ, Hadithi M, Crusius JB, Meijer JW, Duggan DJ, Mulder CJ, Holstege FC, Wijmenga C.

Gut. 2004 Jul;53(7):944-51.

31.

TEAM: a tool for the integration of expression, and linkage and association maps.

Franke L, van Bakel H, Diosdado B, van Belzen M, Wapenaar M, Wijmenga C.

Eur J Hum Genet. 2004 Aug;12(8):633-8.

32.

Exon trapping. Application of a large-insert multiple-exon-trapping system.

Wapenaar MC, Den Dunnen JT.

Methods Mol Biol. 2001;175:201-15. Review. No abstract available.

PMID:
11462836
33.

Characterization of Cxorf5 (71-7A), a novel human cDNA mapping to Xp22 and encoding a protein containing coiled-coil alpha-helical domains.

de Conciliis L, Marchitiello A, Wapenaar MC, Borsani G, Giglio S, Mariani M, Consalez GG, Zuffardi O, Franco B, Ballabio A, Banfi S.

Genomics. 1998 Jul 15;51(2):243-50.

PMID:
9722947
34.

A YAC-based binning strategy facilitating the rapid assembly of cosmid contigs: 1.6 Mb of overlapping cosmids in Xp22.

Wapenaar MC, Schiaffino MV, Bassi MT, Schaefer L, Chinault AC, Zoghbi HY, Ballabio A.

Hum Mol Genet. 1994 Jul;3(7):1155-61.

PMID:
7981686
35.

A submicroscopic deletion in a patient with isolated X-linked ocular albinism (OA1).

Bassi MT, Bergen AA, Wapenaar MC, Schiaffino MV, van Schooneveld M, Yates JR, Charles SJ, Meitinger T, Ballabio A.

Hum Mol Genet. 1994 Apr;3(4):647-8. No abstract available.

PMID:
8069311
36.

A gene from the Xp22.3 region shares homology with voltage-gated chloride channels.

van Slegtenhorst MA, Bassi MT, Borsani G, Wapenaar MC, Ferrero GB, de Conciliis L, Rugarli EI, Grillo A, Franco B, Zoghbi HY, Ballabio A.

Hum Mol Genet. 1994 Apr;3(4):547-52.

PMID:
8069296
37.

A CA-repeat polymorphism near DXS418 (P122).

Van De Vosse E, Booms PF, Vossen RH, Wapenaar MC, Van Ommen GJ, Den Dunnen JT.

Hum Mol Genet. 1993 Dec;2(12):2202. No abstract available.

PMID:
8111402
38.

[Polymorphisms in the pseudoautosomal regions of X and Y in DNA diagnosis].

Sieglová Z, Mrug M, Láblerová M, Wapenaar MC, Weissenbach J, Brdicka R.

Vnitr Lek. 1993 Oct;39(10):959-63. Czech.

PMID:
8236868
39.

The genes for X-linked ocular albinism (OA1) and microphthalmia with linear skin defects (MLS): cloning and characterization of the critical regions.

Wapenaar MC, Bassi MT, Schaefer L, Grillo A, Ferrero GB, Chinault AC, Ballabio A, Zoghbi HY.

Hum Mol Genet. 1993 Jul;2(7):947-52.

PMID:
8364577
40.

A high resolution deletion map of human chromosome Xp22.

Schaefer L, Ferrero GB, Grillo A, Bassi MT, Roth EJ, Wapenaar MC, van Ommen GJ, Mohandas TK, Rocchi M, Zoghbi HY, Ballabio A.

Nat Genet. 1993 Jul;4(3):272-9.

PMID:
8358436
41.

Isolation and mapping of human chromosome 21 cosmids using a probe for RTVL-H retrovirus-like elements.

Meulenbelt I, Wapenaar MC, Patterson D, Vijg J, Uitterlinden AG.

Genomics. 1993 Mar;15(3):492-9.

PMID:
8468043
42.

AK1 detects a VNTR locus in the pseudoautosomal region.

Klink A, Wapenaar M, van Ommen GJ, Rappold G.

Hum Mol Genet. 1993 Mar;2(3):339. No abstract available.

PMID:
8098983
43.

Detection of a new submicroscopic Norrie disease deletion interval with a novel DNA probe isolated by differential Alu PCR fingerprint cloning.

Bergen AA, Wapenaar MC, Schuurman EJ, Diergaarde PJ, Lerach H, Monaco AP, Bakker E, Bleeker-Wagemakers EM, van Ommen GJ.

Cytogenet Cell Genet. 1993;62(4):231-5.

PMID:
8440142
44.

Physical mapping of 14 new DNA markers isolated from the human distal Xp region.

Wapenaar MC, Petit C, Basler E, Ballabio A, Henke A, Rappold GA, van Paassen HM, Blonden LA, van Ommen GJ.

Genomics. 1992 May;13(1):167-75.

PMID:
1349572
45.

Search for the gene responsible for polycystic kidney disease and its clinical consequences.

Breuning MH, Saris JJ, Dauwerse JG, Breslau-Siderius L, Wapenaar MC, van Ommen GJ.

Adv Nephrol Necker Hosp. 1992;21:117-24. Review. No abstract available.

PMID:
1566641
46.

Generation and fluorescent in situ hybridization mapping of yeast artificial chromosomes of 1p, 17p, 17q, and 19q from a hybrid cell line by high-density screening of an amplified library.

Driesen MS, Dauwerse JG, Wapenaar MC, Meershoek EJ, Mollevanger P, Chen KL, Fischbeck KH, van Ommen GJ.

Genomics. 1991 Dec;11(4):1079-87.

PMID:
1783377
47.

Deletions within the pseudoautosomal region help map three new markers and indicate a possible role of this region in linear growth.

Henke A, Wapenaar M, van Ommen GJ, Maraschio P, Camerino G, Rappold G.

Am J Hum Genet. 1991 Oct;49(4):811-9.

48.

P9 (DXYS75) detects a VNTR-type RFLP in the pseudoautosomal region.

Wapenaar MC, Pearson PL, van Ommen GJ.

Nucleic Acids Res. 1990 Jan 25;18(2):384. No abstract available.

49.

Direct nonradioactive in situ hybridization of somatic cell hybrid DNA to human lymphocyte chromosomes.

Kievits T, Devilee P, Wiegant J, Wapenaar MC, Cornelisse CJ, van Ommen GJ, Pearson PL.

Cytometry. 1990;11(1):105-9.

50.

Isolation and characterization of cell hybrids containing human Xp-chromosome fragments.

Wapenaar MC, Kievits T, Meera Khan P, Pearson PL, Van Ommen GJ.

Cytogenet Cell Genet. 1990;54(1-2):10-4.

PMID:
2249469

Supplemental Content

Loading ...
Support Center